bezafibrate

基本解釋

Finally, treatment of type 2 diabetic patients with bezafibrate significantly decreased OPN plasma leels.
最后，苯扎貝特治療2型糖尿病患者可使其血漿OPN水平明顯降低。
Methods:Sample was obtained from 28 patients with hypercholesterolemia(HC) and 10 healthy volunteers. Platelet aggregation (PAgT) and thromboxane B?2(TXB?2) and cAMP in platelets were studied before and after treatment with bezafibrate.
方法：分別在體內(nèi)、外觀察28例高膽固醇血癥（HC）患者血小板聚集試驗(yàn)（PAgT）、凝血口惡烷B2（TXB2）及環(huán)腺苷酸（cAMP）在苯扎貝特作用前后的含量變化，并與10例健康體檢者對照。
This study involved 11,177 patients with CHD who were screened for but not included in the Bezafibrate Infarction Prevention study and had no history of stroke or transient ischemic attack (TIA).
在這項(xiàng)研究中，共募集了經(jīng)普查檢出的冠狀動脈心臟病病人11,177名，這些病人沒有參與到苯扎貝特預(yù)防心梗的研究中，也沒有腦中風(fēng)或暫時(shí)性腦缺血綜合癥的病史。
Keywords Bezafibrate;Generation pHenyloxycarboxylic acid medicine;Synthesis;
苯扎貝特;降脂藥物;合成;
Keywords headspace Gas Chromatography;residual organic solvent;bezafibrate;
頂空毛細(xì)管氣相色譜法;殘留溶劑;苯扎貝特;